Athira Pharma (ATHA) News Today $0.63 -0.01 (-2.05%) (As of 12:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ATHA Energy reveals updated technical report for Angilak uranium projectNovember 25, 2024 | proactiveinvestors.comAthira Pharma’s Regulatory Compliance Challenges Threaten Drug Development PipelineNovember 9, 2024 | tipranks.comAthira exploring strategic alternatives after Alzheimer’s failureNovember 8, 2024 | finance.yahoo.comJMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)November 8, 2024 | markets.businessinsider.comAthira Pharma Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comAthira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business UpdatesNovember 7, 2024 | globenewswire.comUS Penny Stocks: November 2024's Top Picks To ConsiderNovember 4, 2024 | finance.yahoo.comAthira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News SummaryNovember 3, 2024 | benzinga.comAthira Pharma to present results from Phase 2/3 LIFT-AD trialOctober 22, 2024 | markets.businessinsider.comAthira Pharma files $300M mixed securities shelfOctober 22, 2024 | markets.businessinsider.comMizuho Downgrades Athira Pharma (ATHA)September 20, 2024 | msn.comHold Rating on Athira Pharma Amid Strategic Pivot and Clinical UncertaintySeptember 18, 2024 | markets.businessinsider.comAthira Pharma to Cut About 70% of WorkforceSeptember 17, 2024 | marketwatch.comAthira Pharma: A Cautious Hold Amid Strategic Pivot and Clinical ProgressSeptember 17, 2024 | markets.businessinsider.comAthira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative DiseasesSeptember 17, 2024 | globenewswire.comJMP Securities Downgrades Athira Pharma (ATHA)September 5, 2024 | msn.comBTIG Downgrades Athira Pharma (ATHA)September 5, 2024 | msn.comAthira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock SinksSeptember 4, 2024 | benzinga.comAthira Pharma (NASDAQ:ATHA) Stock Rating Lowered by Rodman & RenshawRodman & Renshaw lowered shares of Athira Pharma from a "buy" rating to a "neutral" rating in a research report on Wednesday.September 4, 2024 | marketbeat.comAthira Pharma (ATHA) was downgraded to a Hold Rating at JMP SecuritiesSeptember 4, 2024 | markets.businessinsider.comStocks to Watch: Sportsman's Warehouse Holdings, PagerDuty, Athira PharmaSeptember 3, 2024 | marketwatch.comAthira Shares Plunge After Phase 2/3 Fosgonimeton Trial For Alzheimer's Fails To Meet EndpointsSeptember 3, 2024 | markets.businessinsider.comAthira stock craters 72% on failed study for Alzheimer's drugSeptember 3, 2024 | seekingalpha.comAthira Pharma Alzheimer's Treatment Trial Misses Primary EndpointSeptember 3, 2024 | marketwatch.comAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s DiseaseSeptember 3, 2024 | finance.yahoo.comAthira Pharma's Alzheimer's drug fails in mid-to-late stage trialSeptember 3, 2024 | reuters.comAthira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's DiseaseSeptember 3, 2024 | globenewswire.comAthira Pharma Inc Ordinary SharesAugust 31, 2024 | morningstar.comRodman & Renshaw Initiates Coverage of Athira Pharma (ATHA) with Buy RecommendationAugust 20, 2024 | msn.comShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Decreases By 8.4%Athira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 989,200 shares, a decrease of 8.4% from the July 15th total of 1,080,000 shares. Currently, 2.8% of the company's shares are short sold. Based on an average daily volume of 131,000 shares, the days-to-cover ratio is currently 7.6 days.August 18, 2024 | marketbeat.comHCA Dec 2024 315.000 putAugust 11, 2024 | au.finance.yahoo.comPositive Outlook for Athira Pharma Amid Upcoming Alzheimer’s Drug MilestonesAugust 5, 2024 | markets.businessinsider.comAthira Pharma (NASDAQ:ATHA) Releases Earnings Results, Beats Expectations By $0.05 EPSAthira Pharma (NASDAQ:ATHA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.05.August 3, 2024 | marketbeat.comBuy Rating Affirmed for Athira Pharma Amid Positive LIFT-AD Trial Prospects and Expanding PipelineAugust 2, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Buys 227,278 Shares of Athira Pharma, Inc. (NASDAQ:ATHA)Jacobs Levy Equity Management Inc. grew its stake in shares of Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 84.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 497,475 shares of the company's stock after purchaAugust 2, 2024 | marketbeat.comAthira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business UpdatesAugust 1, 2024 | globenewswire.comAthira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024July 31, 2024 | globenewswire.comAcadian Asset Management LLC Purchases 405,793 Shares of Athira Pharma, Inc. (NASDAQ:ATHA)Acadian Asset Management LLC lifted its holdings in Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 281.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 549,938 shares of the company's stock aJuly 25, 2024 | marketbeat.comAthira Pharma, Inc. (NASDAQ:ATHA) Short Interest UpdateAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 1,010,000 shares, an increase of 13.5% from the May 31st total of 889,500 shares. Based on an average trading volume of 173,900 shares, the days-to-cover ratio is presently 5.8 days. Currently, 2.9% of the shares of the company are sold short.July 1, 2024 | marketbeat.comAthira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano Purchases 15,000 SharesJune 26, 2024 | insidertrades.comInsider Buying: Athira Pharma, Inc. (NASDAQ:ATHA) Director Buys 15,000 Shares of StockAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) Director Kelly A. Romano purchased 15,000 shares of the firm's stock in a transaction that occurred on Friday, June 21st. The stock was bought at an average cost of $2.26 per share, for a total transaction of $33,900.00. Following the completion of the purchase, the director now directly owns 53,315 shares in the company, valued at approximately $120,491.90. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.June 25, 2024 | marketbeat.comAthira Pharma (NASDAQ:ATHA) Rating Reiterated by JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $19.00 price target on shares of Athira Pharma in a research note on Thursday.June 20, 2024 | marketbeat.comPerceptive Advisors LLC Raises Stock Holdings in Athira Pharma, Inc. (NASDAQ:ATHA)Perceptive Advisors LLC increased its position in Athira Pharma, Inc. (NASDAQ:ATHA - Free Report) by 12.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,402,964 shares of the company's stock after acquiring an addiJune 16, 2024 | marketbeat.comAthira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease PatientsJune 12, 2024 | globenewswire.comGlancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)June 10, 2024 | prnewswire.comAthira Pharma, Inc. (NASDAQ:ATHA) Short Interest Down 12.1% in MayAthira Pharma, Inc. (NASDAQ:ATHA - Get Free Report) saw a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 923,300 shares, a drop of 12.1% from the April 30th total of 1,050,000 shares. Based on an average daily trading volume, of 309,500 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.6% of the company's shares are short sold.June 1, 2024 | marketbeat.comAthira Pharma to Participate in Upcoming June ConferencesMay 29, 2024 | globenewswire.comBuy Rating Affirmed on Athira Pharma Amid Promising Alzheimer’s Drug Developments and Strategic AdvancementsMay 20, 2024 | markets.businessinsider.comAthira Pharma Announces Proposed Settlement of Stockholder Derivative ActionMay 17, 2024 | globenewswire.comAthira names new chief medical officer ahead of release of key trial dataMay 17, 2024 | bizjournals.com Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. ATHA Media Mentions By Week ATHA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATHA News Sentiment▼1.000.87▲Average Medical News Sentiment ATHA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATHA Articles This Week▼31▲ATHA Articles Average Week Get Athira Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLSA News Today ANVS News Today RLMD News Today GNLX News Today ORMP News Today AVTX News Today GNTA News Today NVCT News Today FBLG News Today ELYM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATHA) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
